InnoCan Pharma Corporation

Equities

INNO

CA45783P1027

Pharmaceuticals

Delayed Canadian Securities Exchange 01:34:58 2024-02-28 pm EST 5-day change 1st Jan Change
0.32 CAD 0.00% Intraday chart for InnoCan Pharma Corporation +6.67% +3.23%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
InnoCan Pharma Brief: Says "Surge" in revenue Primarily attributable to "Robust" sales performance of Subsidiary, B.I. Sky Global Ltd. MT
InnoCan Pharma Brief: Reporting US$4.083 Million In Revenues for Q3 2023 Vs US$749,000 for Q3 2022, representing an increase of 445% MT
Innocan Pharma Corporation Announces Promising LPT-CBD Safety Indications CI
InnoCan Pharma Completes Second, Final Tranche of Financing; Down Over 3% MT
InnoCan Pharma Corporation announced that it has received CAD 1.627682 million in funding CI
InnoCan Pharma Completes First Tranche Private Placement; Down 4.8% MT
Innocan Pharma Plans Brokered LIFE Offering of Units for Nearly $3 Million MT
InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding CI
InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board CI
Innocan Pharma Corporation Announces Promising Results from Hair Care Cream Efficacy Test CI
Innocan Pharma Corporation Announces Clinical Study Results CI
InnoCan Pharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Innocan Pharma Announces Promising Successful Results in Efficacy Trial of Diabetic Foot Relief Treatment CI
Innocan Pharma Announced "Promising Successful" Results in Efficacy Trial of Diabetic Foot Relief Treatment; Gained 9% Today MT
InnoCan Pharma Corporation announced that it has received CAD 1.934239 million in funding CI
InnoCan Pharma Corporation announced that it expects to receive CAD 1.934239 million in funding CI
InnoCan Pharma Announces Private Placement of Units at a 9% Prime Above Share Price MT
InnoCan Pharma Corporation announced that it has received CAD 3.9606 million in funding CI
InnoCan Pharma Rose 14% Today; Then Says Submitted New Patent Applications for Advanced Pain Relief Technology MT
Innocan Pharma Corporation Submits New Patent Applications for Advanced Pain Relief Technology CI
Innocan Pharma Corp Brief: Citing US$1.3 Million Increase in Revenues Compared to Q1 2022 MT
InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
InnoCan Pharma Corporation Announces Successful Treatment of Billy with Liposomal-CBD Injection in Pre-Clinical Trial CI
Innocan Pharma Corporation Announces the Entering into of A Wide-Scope Commercial Distribution Agreement with UAB Medexy CI
Chart InnoCan Pharma Corporation
More charts
Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
More about the company
  1. Stock
  2. Equities
  3. Stock InnoCan Pharma Corporation - Canadian Securities Exchange
  4. News InnoCan Pharma Corporation
  5. InnoCan Pharma Completes Second, Final Tranche of Financing; Down Over 3%
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW